Free Trial
→ REVEALED FREE: Our top 3 stocks to own in 2025 and beyond (From Weiss Ratings) (Ad)

Obesity Drug Boom, Split Make This Stock a Heavy Bargain

Written by MarketBeat Staff
October 9, 2023

Key Points

  • Rapidly growing demand for Novo Nordisk’s GLP-1 diabetes and obesity treatments are fattening up its financial results.
  • Last month, the company completed a 2-for-1 stock split that put its price under $100.
  • Management raised full-year sales growth outlook to 27% to 33%, reflecting the company's massive market share in a pair of fast-growth markets.
  • Five stocks to consider instead of Novo Nordisk A/S.

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Upgrade Now See Benefits

Already have an account? Log in here.

Should You Invest $1,000 in Novo Nordisk A/S Right Now?

Before you consider Novo Nordisk A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.

While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Novo Nordisk A/S (NVO)
4.7278 of 5 stars		$79.39+5.2%2.05%24.13Hold$112.00
Eli Lilly and Company (LLY)
4.9896 of 5 stars		$807.75+4.4%0.74%68.98Moderate Buy$1,011.37
Walmart (WMT)
4.5134 of 5 stars		$97.34-0.1%0.97%40.39Moderate Buy$106.50
Mondelez International (MDLZ)
4.2931 of 5 stars		$67.24+0.8%2.80%19.66Moderate Buy$70.11
Nestlé (NSRGY)
1.4232 of 5 stars		$104.38-1.0%2.27%N/AHold$91.00
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

ACT FAST! Congress Is POURING Into This Stock
May 23, 2025

ACT FAST! Congress Is POURING Into This Stock

Lawmakers are making big trades again; Chris Markoch shares 3 big congressional buys, including one surprising pick that’s down over 30%.

Watch Video

Recent Videos

Analysts Are Watching These 4 Penny Stocks—You Should Too
Congress Is Pouring Millions Into These 6 Surprising Stocks
3 Dirt-Cheap Stocks in a Market That’s Getting Expensive

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines